Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Livermore, P. A.
Right arrow Articles by Murray, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Livermore, P. A.
Right arrow Articles by Murray, K. J.
Related Collections
Right arrow Vasculitis
Right arrow Vasculitis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 1450-1452
© 2002 British Society for Rheumatology

Paediatric Rheumatology

Anti-tumour necrosis factor therapy associated with cutaneous vasculitis

P. A. Livermore and K. J. Murray

Paediatric Rheumatology Unit, Great Ormond St Hospital for Children, Great Ormond Street, London WC1N 3JH, UK

The first 10% of the full text of this article appears below.

SIR, We read with interest the letter by McCain et al. [1] and we wish to add our experience of a case of probable vasculitis or cutaneous reaction secondary to anti-tumour necrosis factor (anti-TNF) therapy, as has been noted by others. While injection site reactions can occur in up to 20% of patients receiving etanercept [2], more generalized reactions are only recently being recognized [1, 3–6].

We report a Caucasian girl who was referred to our rheumatology unit at 91/2; yr of age in October 1995 with a 6-month history of intermittent daily high-spiking fever, lethargy, evanescent rash accompanying the fever, and joint pain and stiffness. Clinical . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
P. J. Hashkes and R. M. Laxer
Medical Treatment of Juvenile Idiopathic Arthritis
JAMA, October 5, 2005; 294(13): 1671 - 1684.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. Tutar, F. Ekici, N. Nacar, S. Arici, and S. Atalay
Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis
Rheumatology, May 1, 2004; 43(5): 674 - 675.
[Full Text] [PDF]